BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 29550548)

  • 1. Age-related pathology after adenoviral overexpression of the leucine-rich repeat kinase 2 in the mouse striatum.
    Kritzinger A; Ferger B; Gillardon F; Stierstorfer B; Birk G; Kochanek S; Ciossek T
    Neurobiol Aging; 2018 Jun; 66():97-111. PubMed ID: 29550548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging.
    Chen X; Xie C; Tian W; Sun L; Zheng W; Hawes S; Chang L; Kung J; Ding J; Chen S; Le W; Cai H
    Mol Neurodegener; 2020 Feb; 15(1):12. PubMed ID: 32075681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.
    Novello S; Arcuri L; Dovero S; Dutheil N; Shimshek DR; Bezard E; Morari M
    Neurobiol Dis; 2018 Dec; 120():21-33. PubMed ID: 30172844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
    Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
    Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive silencing of LRRK2 kinase activity leads to early glucocerebrosidase deregulation and late impairment of autophagy in vivo.
    Albanese F; Mercatelli D; Finetti L; Lamonaca G; Pizzi S; Shimshek DR; Bernacchia G; Morari M
    Neurobiol Dis; 2021 Nov; 159():105487. PubMed ID: 34419621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
    Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW
    J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
    Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
    J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.
    Xiao Q; Yang S; Le W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1645-57. PubMed ID: 26253900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic LRRK2 requires secondary factors to induce cellular toxicity.
    Lobbestael E; Van den Haute C; Macchi F; Taymans JM; Baekelandt V
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32975566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes.
    Mercatelli D; Bolognesi P; Frassineti M; Pisanò CA; Longo F; Shimshek DR; Morari M
    Pharmacol Res Perspect; 2019 Jun; 7(3):e00484. PubMed ID: 31149340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
    Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
    Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathway-specific dysregulation of striatal excitatory synapses by LRRK2 mutations.
    Chen C; Soto G; Dumrongprechachan V; Bannon N; Kang S; Kozorovitskiy Y; Parisiadou L
    Elife; 2020 Oct; 9():. PubMed ID: 33006315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 G2019S and Parkinson's disease: insight from Neuroinflammation.
    Yao XY; Guan LN; Chen Q; Ren C
    Postgrad Med J; 2023 Dec; 100(1179):4-11. PubMed ID: 37777187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.